文献速递血栓与止血

凝血酶生成用于监测A型血友病止血治疗:一项叙述性综述

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review.
PubMed 文献 · J Thromb Haemost · 2022-01-28

本叙述性综述总结凝血酶生成试验(TGA)用于监测A型血友病不同治疗方式的知识。严重A型血友病因先天性缺乏凝血因子VIII(FVIII)而有出血风险,多数患者使用预防性FVIII浓缩物,其效果可用FVIII活性水平监测,但FVIII活性水平预测临床出血风险价值有限。TGA可整体测量止血平衡,可能更好地指导和监测A型血友病患者的治疗,也可用于测定对旁路制剂和非因子替代治疗的反应,而FVIII活性测定不适合监测这些治疗。

要点

  • TGA可整体测量止血平衡,可能比FVIII活性水平更好地指导和监测A型血友病治疗。
  • TGA可测定对旁路制剂和非因子替代治疗的反应,FVIII活性测定不适合监测这些治疗。
  • 综述总结用TGA监测A型血友病不同治疗方式的知识,涵盖单一治疗和联合使用。

核心结论

  • TGA测量整体止血平衡,可能更好地指导和监测A型血友病患者治疗。
  • TGA可测定对旁路制剂和非因子替代治疗的反应,FVIII活性测定不适合监测这些治疗。

研究设计与样本

  • 叙述性综述,总结用TGA监测A型血友病不同治疗方式的当前知识,涵盖单一治疗和联合使用。

主要发现

  • 严重A型血友病因先天性缺乏FVIII而有自发出血和创伤相关出血风险,多数患者使用预防性FVIII浓缩物。
  • FVIII活性水平预测潜在临床出血风险价值有限,部分患者尽管FVIII谷浓度充足仍发生突破性出血,另一些患者谷浓度低于阈值却不出血。
  • 这种差异可能由促凝血和抗凝血因子个体间差异即所谓止血平衡所致,TGA可整体测量止血平衡。

临床怎么用

  • TGA可能作为指导和监测A型血友病患者治疗的更好工具。
  • TGA可测定对旁路制剂和非因子替代治疗的反应,FVIII活性测定不适合监测这些治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma-related bleeding because of a congenital absence of factor VIII (FVIII). Most severe HA patients use prophylactic FVIII concentrate, the effect of which can be monitored with FVIII activity level measurement. However, FVIII activity level is less valuable in predicting the potential clinical bleeding risk. Some patients still experience breakthrough bleeds despite adequate FVIII trough levels, whereas others do not bleed with trough levels below threshold. This difference may be caused by inter-individual differences in pro- and anticoagulant factors, the so-called hemostatic balance. Thrombin generation assays (TGAs) measure the hemostatic balance as a whole. Thereby, the TGAs may be a better tool in the guidance and monitoring of treatment in HA patients. In addition, TGAs offer the opportunity to determine the response to bypassing agents and treatment with non-factor replacement therapy, in which FVIII activity assays are not suitable for monitoring. This review summarizes the current knowledge about monitoring different HA treatment modalities by TGA, as a single treatment option and when used in a concomitant fashion.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Verhagen MJA, Valke LLFG, Schols SEM, et al. Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review. J Thromb Haemost. 2022. PMID: 35034413. doi:10.1111/jth.15640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。